Sophia Genetics, the global leader in Data Driven Medicine (DDM), announced that five prestigious Belgian hospitals have become members of its clinical genomics community, the leading group in the world for molecular diagnosis.
The five healthcare institutions are:
– AZ Sint Lucas in Ghent
– HistoGeneX in Antwerp
– Institute of Pathology and Genetics in Gosselies
– Saint-Luc University Hospital in Woluwe
– Universitair Ziekenhuis in Brussels
Sophia Genetics will provide these hospitals with leading analytics solutions to diagnose patients of some cancers and inherited conditions faster and more accurately. Its platform, Sophia DDM™, uses the most sophisticated machine learning and mathematical algorithms, to give clinicians the most accurate, speedy and cost-effective means of offering genomic analysis of samples to their patients.
These hospitals and laboratories belong to the national network of genetic centres or pathology laboratories managing genomic information in Belgium. As participants in Sophia Genetics’ clinical genomics community, they and their patients will benefit from the most advanced algorithms to detect even subtle genomic alterations in cancer genes such as base substitutions, copy number alterations, short insertions, deletions and rearrangements.
In an increasing number of cases, early detection of such mutations can help oncologists recommend targeted and more effective treatments to their patients. Furthermore, early detection of these mutations can highlight the potential risk of higher susceptibility to develop hereditary cancers. Angelina Jolie’s personal history, disclosed in the news in March 2015, highlighted the benefits of such approach to prevent ovarian and breast cancers. For some of these Belgian healthcare institutions, Sophia will provide companion diagnostics for products such as AstraZeneca’s drug and PARP inhibitor Olaparib.
Source: Sophia Genetics